Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen added to platinum-cyclophosphamide chemotherapy for advanced ovarian carcinoma
ACTRN12606000300572Phase 3Completed
- Sponsor
- Cancer Council Victoria
- Start
- Jan 1989
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tamoxifen, cisplatin, carboplatin and cyclophosphamide in ovarian cancer and epithelial ovarian cancer (EOC) (2 arms), sponsored by Cancer Council Victoria. Primary endpoint: Time to disease progression. Started Jan 1989; status: completed.
02
Drugs
tamoxifencisplatincarboplatincyclophosphamide
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on ACTRN12606000300572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000300572.